["{\n\"step_by_step_thinking\": \"The question is about the type of study design used to assess the antileukemic activity of a new tyrosine kinase inhibitor in patients with chronic myeloid leukemia in blast crisis. The patients are informed that they would be treated with the drug, and then assigned to successive dose cohorts. This suggests that the patients are not randomly assigned to different treatments or doses, but rather receive a specific dose based on their enrollment order. This is an open-labeled study because all patients know what treatment they are receiving.\",\n\"answer_choice\": \"C: Open-labeled clinical trial\"\n}"]